microRNA146a expression in lupus patients with and without renal complications

Journal of Clinical Laboratory Analysis

Volumn 26, Issue 1, 2012, Pages 35-40

  Hashad, D I ^a   Abdelmagid, M H ^b   Elsherif, S H ^c  

^a Clinical Pathology Department   (Egypt)

^b Rheumatology Department   (Egypt)

^c ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

miRNA; Nephritis activity marker; SLE

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; DOUBLE STRANDED DNA ANTIBODY; MICRORNA 146A; MICRORNA; MIRN146 MICRORNA, HUMAN;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CASE CONTROL STUDY; GENETICS; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; YOUNG ADULT;

ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MICRORNAS; MIDDLE AGED; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84868536948     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20501     Document Type: Article

References (23)

1. Hakkim A, Fürnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. PNAS 2010;107:9813-9818.
2. Mok C. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010;2010:1-11.
3. Soifer H, Rossi J, Sćtrom P. MicroRNAs in disease and potential therapeutic applications. Mol Ther 2007;12:2070-2079.
4. Sonkoly E, Pivarcsi A. microRNAs in inflammation. Int Rev Immunol 2009;28:535-561.
5. Chan EK, Satoh M, Pauley KM. Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: is microRNA-146 all we need? Arthritis Rheum 2009;60:912- 915.
6. Dai Y, HuangYS, Tang M, et al.Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus 2007;16:939-946.
7. Tang Y, LuoX,Cui H, et al.MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins.ArthritisRheum 2009;60:1065- 1075.
8. Calin GA, Croce CM. microRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866.
9. Pauley KM, Cha S, Chan EK. MicroRNA in autoimmunity and autoimmune diseases. J Autoimmun 2009;32:189-194.
10. Hochberg MA. Updating theACRrevised criteria for the classification of systemic lupus erythematosus.ArthritisRheum 1997;40:172.
11. Petri M. Disease activity assessment in SLE: do we have the right instruments? Ann Rheum Dis 2007;66:iii61-iii64.
12. Lacelle C, Riol H, Xu S, et al. Blood sample processing for the study of age-dependent gene expression in peripheral blood mononuclear cells. J Gerontol A Biol Sci Med Sci 2002;57:B285-B287.
13. Nakasa T, Miyaki S, Okubo A, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum 2008;58:1284-1292.
14. -ΔΔCt method. Diagn Mol Pathol 2001;25:402-408.
15. Dai Y, Sui W, Lan H, et al. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int 2009;29:749-754.
16. Te JL, Dozmorov IM, Guthridge JM, et al. Identification of unique microRNA signature associated with lupus nephritis. PLoS ONE 2010;5:1-7.
17. Sonkoly E, Pivarcsi A. microRNAs in inflammation. Int Rev Immunol 2009;28:535-561.
18. López-Hoyos M, Cabeza R, Martínez-Taboada VM. Clinical disease activity and titers of anti-dsDNA antibodies measured by an automated immunofluorescence assay in patients with systemic lupus erythematosus. Lupus 2005;14:505-509.
19. Niewol T, SwedlerW. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005;24:178-181.
20. Niewold T, Clark D, Salloum R, Poole B. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol 2010;2010:1-8.
21. Bagavanta H, Fua S. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol 2009;21:489-494.
22. Dall'Era MC, Cardarelli PM, Preston BT, Witte A, Davis Jr JC. Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 2005;64:1692-1697.
23. Bengtsson A. Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000;9:664-671.